Homepage Top Section1

Keytruda is Merck’s an anti-programmed death receptor-1 (PD-1) therapy that hinders the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It increases the ability of the body’s

Developed using Novavax’ recombinant nanoparticle technology, the vaccine also known as NVX-CoV2373 is a protein-based Covid-19 vaccine candidate which is engineered from the genetic sequence of the initial

Alpine Immune Sciences and Horizon Therapeutics have signed an exclusive licence and collaboration agreement to develop protein-based therapies to treat autoimmune and inflammatory diseases. As agreed, Horizon will

Bristol Myers Squibb has signed a license, development, and commercialisation agreement with clinical-stage biopharmaceutical firm Immatics for the latter’s TCR Bispecific candidate for solid tumours, IMA401. Under the

Prestige BioPharma and Dr. Reddy’s Laboratories have signed a binding agreement to commercialise the former’s trastuzumab (HD201) biosimilar in select Latin America and Southeast Asian countries. Trastuzumab (HD201),

The European Medicines Agency (EMA) has accepted to review Sanofi’s marketing authorization application (MAA) for olipudase alfa to treat acid sphingomyelinase deficiency (ASMD). An investigational enzyme replacement therapy,

Julphar is a pharmaceutical company based in the UAE and has presence in the MENA (Middle East North Africa) region. It will secure exclusive rights to produce and

French company Valneva and IDT Biologika have partnered to manufacture the former’s inactivated vaccine candidate, VLA2001, for Covid-19. The latest move follows an advance purchase agreement signed by

The expanded EUA allows the administration of booster dose to individuals of 18 years of age and older who have received primary dosages. With the same dosage strength